Penbrook Management LLC Sells 19,455 Shares of Exagen Inc. $XGN

Penbrook Management LLC reduced its position in Exagen Inc. (NASDAQ:XGN) by 49.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,910 shares of the company’s stock after selling 19,455 shares during the quarter. Penbrook Management LLC owned about 0.09% of Exagen worth $139,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of XGN. Acadian Asset Management LLC bought a new position in shares of Exagen in the first quarter valued at approximately $25,000. Huntleigh Advisors Inc. lifted its position in Exagen by 16.8% during the first quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company’s stock valued at $298,000 after purchasing an additional 11,939 shares during the last quarter. Finally, Palumbo Wealth Management LLC lifted its position in Exagen by 14.4% during the first quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company’s stock valued at $356,000 after purchasing an additional 12,501 shares during the last quarter. 75.25% of the stock is currently owned by institutional investors.

Exagen Stock Up 0.8%

Shares of NASDAQ XGN opened at $11.04 on Tuesday. The company has a quick ratio of 4.95, a current ratio of 4.95 and a debt-to-equity ratio of 1.06. The firm’s fifty day moving average is $9.97 and its 200 day moving average is $7.62. The company has a market cap of $242.88 million, a price-to-earnings ratio of -12.40 and a beta of 1.54. Exagen Inc. has a 52 week low of $2.38 and a 52 week high of $11.27.

Exagen (NASDAQ:XGN) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.25 million. Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. Exagen has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Exagen Inc. will post -0.88 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on XGN shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 target price on shares of Exagen in a research report on Wednesday, July 30th. Craig Hallum started coverage on shares of Exagen in a research report on Wednesday, July 23rd. They set a “buy” rating and a $12.00 target price for the company. KeyCorp upgraded shares of Exagen from a “sector weight” rating to an “overweight” rating and set a $12.00 target price for the company in a research report on Wednesday, July 30th. B. Riley started coverage on shares of Exagen in a research report on Thursday, September 11th. They set a “buy” rating and a $15.00 target price for the company. Finally, Canaccord Genuity Group lifted their target price on shares of Exagen from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday, July 30th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Exagen presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).